Acasunlimab

DB18932InvestigationalProtein Based Therapies

Acasunlimab is under investigation in clinical trial NCT06046274 (GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1 and Tumor necrosis factor receptor superfamily member 9
Curator reviewed
Also known as: acasunlimab [INN] · DuoBody PDL1x4-1BB · DuoBody-PD-L1x4-1BB
Code names: BNT 311 · GEN-1046

Resolves to

Compound

UNIIH52ITZ9X9DCAS2253937-12-9

Targets

Q9NZQ7CD274Q07011TNFRSF9

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Acasunlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account